163 related articles for article (PubMed ID: 28109694)
1. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis.
Hewes D; Tatomir A; Kruszewski AM; Rao G; Tegla CA; Ciriello J; Nguyen V; Royal W; Bever C; Rus V; Rus H
Exp Mol Pathol; 2017 Apr; 102(2):191-197. PubMed ID: 28109694
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Ciriello J; Tatomir A; Hewes D; Boodhoo D; Anselmo F; Rus V; Rus H
Exp Mol Pathol; 2018 Oct; 105(2):175-180. PubMed ID: 30028960
[TBL] [Abstract][Full Text] [Related]
3. SIRT1 is decreased during relapses in patients with multiple sclerosis.
Tegla CA; Azimzadeh P; Andrian-Albescu M; Martin A; Cudrici CD; Trippe R; Sugarman A; Chen H; Boodhoo D; Vlaicu SI; Royal W; Bever C; Rus V; Rus H
Exp Mol Pathol; 2014 Apr; 96(2):139-48. PubMed ID: 24397908
[TBL] [Abstract][Full Text] [Related]
4. RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Kruszewski AM; Rao G; Tatomir A; Hewes D; Tegla CA; Cudrici CD; Nguyen V; Royal W; Bever CT; Rus V; Rus H
Exp Mol Pathol; 2015 Dec; 99(3):498-505. PubMed ID: 26407760
[TBL] [Abstract][Full Text] [Related]
5. JNK and phosphorylated Bcl-2 predict multiple sclerosis clinical activity and glatiramer acetate therapeutic response.
Anselmo F; Tatomir A; Boodhoo D; Mekala AP; Nguyen V; Rus V; Rus H
Clin Immunol; 2020 Jan; 210():108297. PubMed ID: 31698073
[TBL] [Abstract][Full Text] [Related]
6. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
Ziemssen T; Calabrese P; Penner IK; Apfel R
J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
[TBL] [Abstract][Full Text] [Related]
7. IL-27: a potential biomarker for responders to glatiramer acetate therapy.
Mindur JE; Valenzuela RM; Yadav SK; Boppana S; Dhib-Jalbut S; Ito K
J Neuroimmunol; 2017 Mar; 304():21-28. PubMed ID: 27449853
[TBL] [Abstract][Full Text] [Related]
8. B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis.
Tacke S; Braune S; Rovituso DM; Ziemssen T; Lehmann PV; Dikow H; Bergmann A; Kuerten S
Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33707177
[TBL] [Abstract][Full Text] [Related]
9. 12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
Signoriello E; Iardino P; Casertano S; De Lucia D; Pucciarelli A; Puoti G; Chiosi E; Lus G
J Neuroimmunol; 2020 Nov; 348():577385. PubMed ID: 32927398
[TBL] [Abstract][Full Text] [Related]
10. Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate.
Rojas-Morales E; Santos-López G; Hernández-Cabañas S; Arcega-Revilla R; Rosas-Murrieta N; Jasso-Miranda C; El-Kassis EG; Reyes-Leyva J; Sedeño-Monge V
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905601
[TBL] [Abstract][Full Text] [Related]
11. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
Valenzuela RM; Kaufman M; Balashov KE; Ito K; Buyske S; Dhib-Jalbut S
J Neuroimmunol; 2016 Nov; 300():59-65. PubMed ID: 27390072
[TBL] [Abstract][Full Text] [Related]
12. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
Matute-Blanch C; Río J; Villar LM; Midaglia L; Malhotra S; Álvarez-Cermeño JC; Vidal-Jordana A; Montalban X; Comabella M
J Neuroimmunol; 2017 Feb; 303():62-65. PubMed ID: 28063616
[TBL] [Abstract][Full Text] [Related]
13. The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.
Tatomir A; Talpos-Caia A; Anselmo F; Kruszewski AM; Boodhoo D; Rus V; Rus H
Immunol Res; 2017 Dec; 65(6):1103-1109. PubMed ID: 29116612
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis.
Achiron A; Feldman A; Gurevich M
Dis Markers; 2009; 27(2):63-73. PubMed ID: 19893201
[TBL] [Abstract][Full Text] [Related]
15. Global DNA Methylation and Hydroxymethylation Levels in PBMCs Are Altered in RRMS Patients Treated with IFN-β and GA-A Preliminary Study.
Reyes-Mata MP; Mireles-Ramírez MA; Griñán-Ferré C; Pallàs M; Pavón L; Guerrero-García JJ; Ortuño-Sahagún D
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240421
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.
Boster AL; Ford CC; Neudorfer O; Gilgun-Sherki Y
Expert Rev Neurother; 2015 Jun; 15(6):575-86. PubMed ID: 25924547
[TBL] [Abstract][Full Text] [Related]
17. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C
BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
[TBL] [Abstract][Full Text] [Related]
20. The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Rovituso DM; Duffy CE; Schroeter M; Kaiser CC; Kleinschnitz C; Bayas A; Elsner R; Kuerten S
Sci Rep; 2015 Sep; 5():14265. PubMed ID: 26387426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
